Taken together, these data indicate that although a CD133+ immunophenotype is not restricted to MLLr ALL, PROM1/CD133 is aberrantly expressed in a large subset of cell lines and MLLr leukemia patients, particularly those associated with MLL-AF4 and MLL-ENL fusion proteins. This evidence concerns the gene MLLT1 and leukemia.